OncLive TV

Francisco J. Hernandez-Ilizaliturri, MD, discusses the design of an observational study investigating immunologic changes with venetoclax in CLL.

John H. Strickler, MD, discusses the preliminary efficacy of sotorasib in combination with multiple agents across tumor types harboring KRAS G12C mutations.

Neelam Desai, MD, highlights the phase 3 PATINA study evaluating a palbociclib-based regimen in HR-positive/HER2-positive metastatic breast cancer.

Paul G. Richardson, MD, discusses the activity of quadruplet regimens containing daratumumab or isatuximab in patients with 1q-amplified multiple myeloma.

Matthew Cortese, MD, MPH, discusses the next steps for the multiomic evaluation of venetoclax activity in chronic lymphocytic leukemia.

Marc Matrana, MD, discusses how the expansion of the frontline RCC treatment paradigm opens the door to further questions regarding personalized treatment.

John M. Burke, MD, discusses the challenges associated with using venetoclax for CLL management across both community and academic oncology settings.

Bhagirathbhai Dholaria, MBBS, discusses the mechanism of action of P-BCMA-ALLO1 in relapsed/refractory multiple myeloma.

David M. Swoboda, MD, discusses the roles of available TKIs for the treatment of patients with chronic myeloid leukemia.

Joseph Vento, MD, highlights the role of IO/TKI combinations for the treatment of patients with non–clear cell renal cell carcinoma.

Kiavasch Mohammad Nejad Farid, MD, discussed the clinical utility of tabelecleucel in relapsed/refractory post-transplant lymphoproliferative disorder.

Elena Maroto-Martin, PhD, discusses the mechanism of action and therapeutic rationale for an MZB1-targeted CAR T-cell therapy in of multiple myeloma and Waldenström macroglobulinemia.

Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in patients with HER2-low and -ultralow unresectable or metastatic breast cancer.

Kanwarpal S. Kahlon, MD, discusses the benefits of the availability of generic eltrombopag formulations for aplastic anemia and immune thrombocytopenia.

Azka Ali, MD, discusses the need to refine predictive strategies for endocrine sensitivity in HER2-low metastatic breast cancer.

Ryan T. Merrell, MD, discusses current treatment modalities for gliomas in recognition of Brain Tumor Awareness Month.

Himchandana Atluri, MD, details factors to consider ahead of TKI selection in patients with chronic myeloid leukemia.

Paolo Tarantino, MD, PhD, discusses the need for prospective clinical trials to identify treatments for HER2+ breast cancer following progression on T-DXd.

I. Alex Bowman, MD, discusses the differences in disease presentation between ccRCC and non-ccRCC, as well as standard treatments for these subtypes.

R. Lor Randall, MD, FASCO, discusses key areas of consensus discussed at the Annual Birmingham Orthopedic Oncology Meeting.

Charles B. Nguyen, MD, discusses the evolving landscape of adjuvant therapy in localized clear cell renal cell carcinoma.

S. Daniel Haldar, MD, explains the future directions for evaluating NeoAg-VAX in colorectal and pancreatic cancer.

Seema A. Bhat, MD, discusses selecting between liso-cel and pirtobrutinib in relapsed/refractory CLL.

Brad Kahl, MD, discusses the ongoing unmet needs in the treatment of mantle cell lymphoma.

Kelly E. McCann, MD, PhD, discusses the biologic heterogeneity within HER2-positive breast cancer and highlights the clinical implications of HR status in this disease subset.

Tanios S. Bekaii-Saab, MD, FACP, discusses the use of tislelizumab plus chemotherapy in unresectable or metastatic ESCC.

Chad Tang, MD, discusses potential roadblocks for the clinical use of metastasis-directed radiotherapy for patients with oligometastatic ccRCC.

Vivek G. Patel, MD, discusses the potential advantages of subcutaneous bispecific antibodies that are being evaluated in frontline follicular lymphoma.

Andrew Ip, MD, discusses how the limitations of real-world studies reveal gaps in LBCL research that future CAR T-cell therapy clinical trials may address.